CY1107836T1 - Φαρμακευτικη συνθεση η οποια περιλαμβανει ενωση συμπυκνωμενης ινδολης - Google Patents

Φαρμακευτικη συνθεση η οποια περιλαμβανει ενωση συμπυκνωμενης ινδολης

Info

Publication number
CY1107836T1
CY1107836T1 CY20071101602T CY071101602T CY1107836T1 CY 1107836 T1 CY1107836 T1 CY 1107836T1 CY 20071101602 T CY20071101602 T CY 20071101602T CY 071101602 T CY071101602 T CY 071101602T CY 1107836 T1 CY1107836 T1 CY 1107836T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
indola
concentrated
composition including
Prior art date
Application number
CY20071101602T
Other languages
English (en)
Inventor
Philip Christopher Buxton
Schie Dirk Marinus J Van
Seona Thomson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Priority claimed from PCT/GB2001/003544 external-priority patent/WO2002011766A2/en
Priority claimed from EP01954214A external-priority patent/EP1313481B1/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CY1107836T1 publication Critical patent/CY1107836T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Μία φαρμακευτική σύνθεση η οποία περιλαμβάνει Ν-[(1-nβουτυλο-4-πιπεριδινυλο)μεθυλο]-3,4-διϋδρο-2Η-[1,3]-οξαζινο[3,2-α]ινδολο-10-καρβοξαμίδιο (SB207266) ή ένα φαρμακευτικά αποδεκτό άλας του σε συνδυασμό με έναν ή περισσότερους φαρμακευτικά αποδεκτούς φορείς, όπου τουλάχιστον κάποιο από το SB 207266 ή το άλας του είναι σε κοκκοποιημένη μορφή. Κατά προτίμηση, ένα πληρωτικό ή/και ένας σύνδεσμος είναι επίσης παρόντα.
CY20071101602T 2000-08-08 2007-12-18 Φαρμακευτικη συνθεση η οποια περιλαμβανει ενωση συμπυκνωμενης ινδολης CY1107836T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
PCT/GB2001/003544 WO2002011766A2 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
EP01954214A EP1313481B1 (en) 2000-08-08 2001-08-08 Pharmaceutical composition comprising condensed indole compound

Publications (1)

Publication Number Publication Date
CY1107836T1 true CY1107836T1 (el) 2013-06-19

Family

ID=27255838

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101602T CY1107836T1 (el) 2000-08-08 2007-12-18 Φαρμακευτικη συνθεση η οποια περιλαμβανει ενωση συμπυκνωμενης ινδολης

Country Status (12)

Country Link
US (3) US20030032640A1 (el)
EP (2) EP1867333A1 (el)
JP (1) JP2008247915A (el)
KR (1) KR100896563B1 (el)
CN (2) CN1268340C (el)
AT (1) ATE374027T1 (el)
BR (1) BR0113169A (el)
CY (1) CY1107836T1 (el)
HK (1) HK1056998A1 (el)
MX (1) MXPA03001207A (el)
NZ (1) NZ535261A (el)
PT (1) PT1313481E (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001210A (es) * 2000-08-07 2004-08-12 Smithkline Beecham Corp Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.
NZ534333A (en) * 2002-02-14 2006-05-26 Glaxo Group Ltd Pharmaceutical composition comprising N-[(1-n-butyl-4-piperidinyl) methyl]-3,4-dihydro-2H-[1, 3]oxazino[3, 2-a]indole-10-carboxamide or salt, and process for preparing thereof comprising dry granulation
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
ES2758624T3 (es) * 2009-02-12 2020-05-06 Fuji Chem Ind Co Ltd Composición de partículas desintegrantes y material de desintegración rápida moldeado por compresión que comprende la misma
TW201129386A (en) 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
EP3007680B1 (en) * 2013-06-14 2020-02-19 CONARIS research institute AG Extended release nicotinamide formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
DE3332830A1 (de) * 1982-09-16 1984-03-22 The Upjohn Co., 49001 Kalamazoo, Mich. Verwendung von benzodiazepinen zur bekaempfung oder bei der behandlung von panikzustaenden
US4569852A (en) * 1983-08-23 1986-02-11 Warner-Lambert Company Maintenance of flavor intensity in pressed tablets
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
EP0376331A3 (en) * 1988-12-29 1991-03-13 Asahi Kogaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
PT884319E (pt) * 1992-03-12 2004-09-30 Smithkline Beecham Plc N-¬(1-n-butil-4-piperidil)metil|-3,4-di-hidro-2h-¬1,3|oxazino¬3,2-a|indole-10-carboxamida ou um seu sal farmaceuticamente aceitavel
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules

Also Published As

Publication number Publication date
BR0113169A (pt) 2003-07-15
ATE374027T1 (de) 2007-10-15
US20060057218A1 (en) 2006-03-16
NZ535261A (en) 2004-12-24
KR20030023745A (ko) 2003-03-19
CN1679583A (zh) 2005-10-12
EP1867333A1 (en) 2007-12-19
PT1313481E (pt) 2008-01-02
JP2008247915A (ja) 2008-10-16
MXPA03001207A (es) 2004-08-12
EP1872785A1 (en) 2008-01-02
KR100896563B1 (ko) 2009-05-07
CN1458845A (zh) 2003-11-26
US20030032640A1 (en) 2003-02-13
HK1056998A1 (en) 2004-03-12
US20050148582A1 (en) 2005-07-07
CN1268340C (zh) 2006-08-09

Similar Documents

Publication Publication Date Title
CY1107836T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενωση συμπυκνωμενης ινδολης
UA66952C2 (uk) N-(5,7-диметокси[1,2,4]триазоло[1,5-a]піримідин-2-іл)арилсульфонамід, спосіб його одержання, композиція на його основі та спосіб боротьби з небажаною рослинністю
DE68910773D1 (de) Granulate mit Kern und ihre Herstellung.
TNSN94058A1 (fr) Nouveaux composes
LU91563I2 (fr) Combinaisson comprenant de l'aliskiren, comme baselibre ou comme un de ses sels pharmaceutiquement acceptables, et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables-Rasilez HCT
EP0904781A3 (en) Improved pharmaceutical composition comprising fenofibrate
WO2000055125A3 (en) N-cyanomethyl amides as protease inhibitors
BR9713871A (pt) Tablete detergente revestido
ATE322179T1 (de) Granulierter süssstoff
PT1194140E (pt) Composicao farmaceutica contendo fenofibrato e processo de preparacao
SE0001151D0 (sv) Method for producing a controlled-release composition
MY130208A (en) Quetiapine granules
BG103881A (en) Method for the preparation of elurbiprophene pastills
HUP0001313A3 (en) Process for the crystallization of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one
ID30484A (id) Turunan 4-heterosikliksulfonamidil 6 metoksi 5 (2 metoksi fenoksi) 2 piridil-pirimidin, pembuatannya dan penggunaan sebagai antagonis reseptor endotelin
AU1054500A (en) N-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives, their preparation and their use as selective mglur1 antagonists
DK1073673T3 (da) Hidtil ukendte octahydro-6, 10-dioxo-6H-pyridazino [1,2-a] [1,2] - diazepin-1-carboxylsyre-derivater, fremgangsmåde til deres fremstilling og deres anvendelse til fremstilling af terapeutisk aktive forbindelser
BRPI0413768A (pt) processo para preparar gránulos sólidos e gránulo de fosforoamidotioato quimicamente estável
MA26575A1 (fr) Nouveaux derives de l'echinocandine, leur procede de preparation et leur application comme anti-fongicides.
ES2160893T3 (es) Procedimiento y compuestos intermedios para la preparacion de compuestos de fluoroolefinas plaguicidas.
ES2174573T3 (es) Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas.
DE59903063D1 (de) Semi-hydrochlorid von 8-cyan-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluor-1, 4-dihydro-4- oxo-3- chinolincarbonsäure
FI20030379A0 (fi) Uusi farmaseuttinen koostumus
HUP9702475A3 (en) Quinoline, isoquinoline, quinazoline, benzoxazine derivatives substituted with sulfonamide group, process for production thereof and pharmaceutical compositions containing them
ATE247963T1 (de) Medikament zur behandlung von glaukoma und ischämischer retinopathie